← Back to Calendar

Geron Corporation Q1 2026 Earnings

Geron Corporation · $GERN

Standard Review Earnings

PDUFA Date

May 7, 2026

Time Remaining

44 days

Review Type

Standard (10 mo)

Indication

Q1 2026 earnings + RYTELO commercial + sBLA update

Key Notes

Q1 2026 earnings expected ~May 2026. Key updates: RYTELO Q1 revenue trajectory vs $220M–$240M guidance; MDS sBLA PDUFA April 15 outcome expected to be known; IMpactMF Phase 3 OS data update.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar